Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
January 1996

Results of 280 Liver Resections for Hepatocellular Carcinoma

Author Affiliations

From the Departments of Surgery II (Drs Takenaka, Kawahara, Yamamoto, Itasaka, Shirabe, Nishizaki, Yanaga, and Sugimachi) and Pathology II (Drs Kajiyama and Maeda), Faculty of Medicine, Kyushu University, Fukuoka, Japan.

Arch Surg. 1996;131(1):71-76. doi:10.1001/archsurg.1996.01430130073014

Objective:  To evaluate the recent results of liver resection in patients with hepatocellular carcinoma.

Design:  Retrospective study.

Setting:  A university hospital in Japan.

Patients:  Two hundred eighty patients who underwent liver resection with complete extirpation of hepatocellular carcinoma from 1985 to 1993.

Main Outcome Measures:  Morbidity and survival after operation and the pathologic features of hepatocellular carcinoma according to the TNM classification of the International Union Against Cancer.

Results:  More than 40% of the patients with stages I and II disease underwent a partial resection of the liver, whereas 50% of those with stages III and IVA were operated on with more than a bisegmentectomy. Fifty percent of all patients had no postoperative complications. The morbidities included intra-abdominal abscess (7%), bile leakage (5%), and hepatic failure (4%, of whom half died; mortality rate, 2%). Histopathologically, 32% of the stage I tumors were well differentiated (grade 1), while, in stage III, 56% had portal invasion and 61% had daughter lesions in the liver. The cumulative survival rates of patients with stages I, II, and III disease and all patients at 5 years were 69%, 52%, 32%, and 50%, respectively, while the disease-free survival rates at 5 years were 38%, 34%, 17%, and 29%, respectively.

Conclusion:  The recent results of liver resection for hepatocellular carcinoma are generally satisfactory; however, the recurrence rate is still high.(Arch Surg. 1996;131:71-76)